RT Journal Article
SR Electronic
T1 Blood biomarker score identifies individuals at high risk for severe COVID-19 a decade prior to diagnosis: metabolic profiling of 105,000 adults in the UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.02.20143685
DO 10.1101/2020.07.02.20143685
A1 Nightingale Health UK Biobank Initiative
A1 Julkunen, Heli
A1 Cichońska, Anna
A1 Slagboom, P. Eline
A1 Würtz, Peter
YR 2020
UL http://medrxiv.org/content/early/2020/07/03/2020.07.02.20143685.abstract
AB Background Identification of healthy people at high risk for severe COVID-19 is a global health priority. We investigated whether blood biomarkers measured by high-throughput metabolomics could be predictive of severe pneumonia and COVID-19 hospitalisation years after the blood sampling.Methods Nuclear magnetic resonance metabolomics was used to quantify a comprehensive biomarker profile in 105 146 plasma samples collected in the UK Biobank during 2007–2010 (age range 39–70). The biomarkers were tested for association with severe pneumonia (2507 cases, defined as diagnosis in hospital or death record occurring during a median of 8.1-year follow-up) and with severe COVID-19 (195 cases, defined as diagnosis in hospital between mid-March to mid-June 2020). A multi-biomarker score was derived for prediction of severe pneumonia based on half of the study population and validated in the other half. We explored how this biomarker score relates to the risk of severe COVID-19.Findings The biomarker associations with risk of severe COVID-19 followed an overall pattern similar to associations with risk of severe pneumonia (correlation 0.83). The multi-biomarker score, comprised of 25 blood biomarkers including inflammatory proteins, fatty acids, amino acids and advanced lipid measures, was strongly associated with risk of severe pneumonia (odds ratio 1.67 per SD [95% confidence interval 1.59–1.76]; 3.8-fold risk increase for individuals in upper vs lower quintile). The multi-biomarker score was also associated with risk of severe COVID-19 (odds ratio 1.33 per SD [1.17–1.53]; 2.5-fold risk for upper vs lower quintile) and remained significant when adjusting for body mass index, smoking, and existing respiratory and cardiometabolic diseases. Mimicking the decade lag from blood sampling to COVID-19, severe pneumonia events occurring after 7–11 years associated with the multi-biomarker score to a similar magnitude (odds ratio 1.43 per SD [1.29–1.59]; 2.6-fold risk for upper vs lower quintile) as for severe COVID-19. Interpolating to a screening scenario today, the magnitude of association of the multi-biomarker score was 3 times higher for short-term risk of severe pneumonia (odds ratio 2.21 per SD [1.95–2.50]; 8.0-fold risk for upper vs lower quintile in analysis of events during first 2 years after blood sampling).Interpretation In decade-old blood samples from the UK Biobank, a multi-biomarker score measured by high-throughput metabolomics is indicative of the risk for severe COVID-19. The molecular signature of biomarker changes reflective of risk for severe COVID-19 is similar to that for severe pneumonia, in particular when accounting for the time lag to the COVID-19 pandemic. The even stronger association of the biomarker score with 2-year risk for severe pneumonia lends support to promising screening possibilities for identifying people at high risk for severe COVID-19.Competing Interest StatementHJ, AC, and PW are employees of Nightingale Health, Ltd, a company offering nuclear magnetic resonance-based biomarker profiling. AC and PW hold stock options or shares in Nightingale Health, Ltd.Funding StatementThe work was funded by Nightingale Health, Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available from UK Biobank, with the metabolomics data becoming public for the research community in early 2021. https://www.ukbiobank.ac.uk https://nightingalehealth.com